Los Angeles Capital Management
VRDN icon

Los Angeles Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Los Angeles Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
60,846
+60,373
+12,764% +$973K ﹤0.01% 717
2026
Q1 		$9.25K Sell
473
-15,315
-97% -$455K ﹤0.01% 1973
2025
Q4 		$374K Buy
+15,788
New +$433K ﹤0.01% 1011

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Los Angeles Capital Management's VRDN Position: Q2 2026 in Review

Los Angeles Capital Management increased its Viridian Therapeutics (VRDN) stake by 12,764% in Q2 2026, buying an estimated $973K and bringing the position to 60,846 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #717.

Los Angeles Capital Management first reported a position in VRDN in Q4 2025 and has held it in 3 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Los Angeles Capital Management held 60,846 shares of Viridian Therapeutics worth $1.12M as of Q2 2026.
  • Los Angeles Capital Management bought 60,373 Viridian Therapeutics shares in Q2 2026, an estimated $973K.
  • Viridian Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #717 holding.
  • Los Angeles Capital Management first reported a position in Viridian Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.